Stockreport

Keros Therapeutics Announces Initial Topline Results from the Phase 1 Clinical Trial of KER-065 in Healthy Volunteers [Yahoo! Finance]

Keros Therapeutics, Inc. - common stock  (KROS) 
PDF Clinical data from this trial, together with preclinical data, support the therapeutic potential of KER-065 for broad impact in Duchenne muscular dystrophy (“DMD”) and [Read more]